Photo: partnering meetings at BIO 2018.
6th, June 2018
PROALT has participated in the partnering event at BIO International Convention in Boston, MA (USA), to present the latest advances of COLODETECT, the non-invasive test in development by the company that will allow early detection of colorectal cancer (CCR) in patients affected by this disease, even when clinical symptoms are still not visible. The test will initiate soon the clinical validation process, with the focus on launching the product on the market after obtaining the CE mark (IVD). Initially it is planned to be marketed in Europe, and later in the United States, Australia and Canada.

On the therapeutic area, PROALT is advancing the preclinical phase of its therapeutic program with monoclonal antibodies for the treatment of colorectal, breast and melanoma metastatic tumors.